References
- Garrido-Mesa N, Zarzuelo A, Gálvez J. Minocycline: far beyond an antibiotic. Br J Pharmacol 2013;169:337–352
- Arvin KL, Han BH, Du Y, et al. Minocycline markedly protects the neonatal brain against hypoxic-ischemic injury. Ann Neurol 2002;52:54–61
- Du Y, Ma Z, Lin S, et al. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson’s disease. Proc Natl Acad Sci USA 2001;98:14669–14674
- Yang L, Kim JH, Kovacs KD, et al. Minocycline inhibition of photoreceptor degeneration. Arch Ophthalmol 2009;127:1475–1480
- Levkovitch-Verbin H, Kalev-Landoy M, Habot-Wilner Z, Melamed S. Minocycline delays death of retinal ganglion cells in experimental glaucoma and after optic nerve transection. Arch Ophthalmol 2006;124:520–526
- Sun C, Li XX, He XJ, et al. Neuroprotective effect of minocycline in a rat model of branch retinal vein occlusion. Exp Eye Res 2013;113:105–116
- Krady JK, Basu A, Allen CM, et al. Minocycline reduces proinflammatory cytokine expression, microglial activation, and caspase-3 activation in a rodent model of diabetic retinopathy. Diabetes 2005;54:1559–1565
- Cukras CA, Petrou P, Chew EY, et al. Oral minocycline for the treatment of diabetic macular edema (DME): results of a phase I/II clinical study. Invest Ophthalmol Vis Sci 2012;53:3865–3874
- Parvaresh MM, Ghiasian L, Falavarjani KG, et al. Normal values of standard full field electroretinography in an Iranian population. J Ophthalmic Vis Res 2009;4:97–101
- Manzano RP, Peyman GA, Khan P, Kivilcim M. Testing intravitreal toxicity of bevacizumab (Avastin). Retina 2006;26:257–261
- Aydin E, Kazi AA, Peyman GA, et al. Retinal toxicity of intravitreal doxycycline. A pilot study. Arch Soc Esp Oftalmol 2007;82:223–228
- Hollborn M, Wiedemann P, Bringmann A, Kohen L. Chemotactic and cytotoxic effects of minocycline on human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 2010;51:2721–2729